ID   anti-ULBP6/2/5
AC   CVCL_F0AD
SY   WT-anti-ULBP6/2/5
DR   ABCD; ABCD_BF023
RX   PubMed=40116579;
CC   Monoclonal antibody isotype: Not specified.
CC   Monoclonal antibody target: UniProtKB; Q5VY80; Human RAET1L.
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_C561 ! Sp2/mIL-6
CA   Hybridoma
DT   Created: 14-08-25; Last updated: 14-08-25; Version: 1
//
RX   PubMed=40116579; DOI=10.1158/2767-9764.CRC-24-0478; PMCID=PMC11927390;
RA   Benjamin, Joel S.
RA   Jarret, Abigail
RA   Bharill, Shashank
RA   Fontanillas, Pierre
RA   Yadav, Shruti
RA   Sen, Debasish
RA   Ayupova, Dina
RA   Kellar, Danielle
RA   Tilk, Susanne
RA   Hom, Clifford
RA   Bahrami-Dizicheh, Zahra
RA   Chen, I-Ling
RA   Diep, Anh N.
RA   Shi, Shi
RA   Ivic, Nives
RA   Bonnans, Caroline
RA   Owyang, Alex
RA   Sood, Pranidhi
RA   Fuh, Germaine
RA   Schmidt, Maike
RA   Gerrick, Kimberline Y.
RA   Koenig, Patrick
RA   Poggio, Mauro
RG   23andMe Research Team;
RT   "23ME-01473, an Fc effector-enhanced anti-ULBP6/2/5 antibody, restores
RT   NK cell-mediated antitumor immunity through NKG2D and FcgammaRIIIa
RT   activation.";
RL   Cancer Res. Commun. 5:476-495(2025).
//